JACKSONVILLE, Fla. — The U.S. Food and Drug Administration (FDA) has agreed to allow Mayo Clinic to use an automated bioreactor-based stem cell production platform on its campus in Jacksonville, Florida. This enables the Mayo Clinic Center for Regenerative Medicine to produce cells from the bone marrow of a stem cell donor in quantities large enough to make several doses that can be used as treatments in clinical trials.
Continue reading the full article atMayo Clinic News Network
Hello @mayoclinicchestsurgeryteam, This is great news for many who have hopes of one day being able to receive stem cell treatment in hope of one day providing a healing process for incurable diseases. Thanks Mayo Clinic!!!!